MDIT — Medite Cancer Diagnostics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Medite Cancer Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2013 December 31st	2014 December 31st	2015 December 31st	2016 December 31st	2017 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9.96	11	9.89	9.24	6.81
Cost of Revenue
Gross Profit	4.21	3.82	3.8	3.63	0.162
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	9.66	11.4	10.5	10.9	13.3
Operating Profit	0.294	-0.394	-0.599	-1.66	-6.48
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	0.073	-0.595	-0.781	-2.29	-7.3
Provision for Income Taxes
Net Income After Taxes	0.054	-0.699	-0.859	-2.16	-6.81
Net Income Before Extraordinary Items
Net Income	0.054	-0.699	-0.859	-2.16	-6.81
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	0.054	-0.808	-0.937	-2.25	-6.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.004	-0.045	-0.046	-0.105	-0.261
Dividends per Share